Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Terns Pharmaceuticals (Nasdaq: TERN) has appointed Heather Turner, J.D., former CEO of Carmot Therapeutics, to its Board of Directors. Turner brings 25 years of biotechnology experience, most recently leading Carmot's $3.1 billion acquisition by Roche. She replaces Ann E. Taylor, M.D., who is stepping down after three years of service. Turner's expertise spans obesity and oncology sectors, with previous leadership roles at Lyell Immunopharma, Sangamo Therapeutics, and other biotech companies. The appointment aims to strengthen Terns' strategic development of small-molecule product candidates for serious diseases.
Terns Pharmaceuticals (Nasdaq: TERN) ha nominato Heather Turner, J.D., ex CEO di Carmot Therapeutics, nel suo Consiglio di Amministrazione. Turner porta con sé 25 anni di esperienza nel settore biotecnologico, avendo recentemente guidato l'acquisizione di Carmot da 3,1 miliardi di dollari da parte di Roche. Sostituisce Ann E. Taylor, M.D., che si dimette dopo tre anni di servizio. L'esperienza di Turner abbraccia i settori dell'obesità e dell'oncologia, con precedenti ruoli di leadership in Lyell Immunopharma, Sangamo Therapeutics e altre aziende biotecnologiche. La nomina mira a rafforzare lo sviluppo strategico di Terns dei candidati a prodotti a piccole molecole per malattie gravi.
Terns Pharmaceuticals (Nasdaq: TERN) ha nombrado a Heather Turner, J.D., ex CEO de Carmot Therapeutics, en su Junta Directiva. Turner aporta 25 años de experiencia en biotecnología, habiendo liderado recientemente la adquisición de Carmot por 3.1 mil millones de dólares por Roche. Ella reemplaza a Ann E. Taylor, M.D., quien renuncia después de tres años de servicio. La experiencia de Turner abarca los sectores de obesidad y oncología, con roles de liderazgo previos en Lyell Immunopharma, Sangamo Therapeutics y otras empresas biotecnológicas. La nominación tiene como objetivo fortalecer el desarrollo estratégico de Terns de candidatos a productos de pequeñas moléculas para enfermedades graves.
Terns Pharmaceuticals (Nasdaq: TERN)이 Heather Turner, J.D.를 이사회의 구성원으로 임명했습니다. Turner는 Carmot Therapeutics의 전 CEO로 25년의 생명공학 경험을 갖고 있으며, 최근에는 Roche에 의해 31억 달러에 Carmot를 인수하는 데 조력했습니다. 그녀는 3년간의 서비스를 마친 Ann E. Taylor, M.D.를 대체합니다. Turner의 전문성은 비만 및 종양학 분야에 걸쳐 있으며, Lyell Immunopharma, Sangamo Therapeutics 등 다른 생명공학 회사에서 리더십 역할을 수행했습니다. 이번 임명은 심각한 질병을 위한 소분자 제품 후보의 전략적 개발을 강화하는 데 목적을 두고 있습니다.
Terns Pharmaceuticals (Nasdaq: TERN) a nommé Heather Turner, J.D., ancienne CEO de Carmot Therapeutics, au sein de son Conseil d'Administration. Turner apporte 25 ans d'expérience dans le secteur des biotechnologies, ayant récemment dirigé l'acquisition de Carmot par Roche pour 3,1 milliards de dollars. Elle remplace Ann E. Taylor, M.D., qui démissionne après trois ans de service. L'expertise de Turner couvre les secteurs de l'obésité et de l'oncologie, avec des rôles de leadership précédents chez Lyell Immunopharma, Sangamo Therapeutics et d'autres entreprises biopharmaceutiques. La nomination vise à renforcer le développement stratégique de Terns concernant les candidats à des produits à petites molécules pour des maladies graves.
Terns Pharmaceuticals (Nasdaq: TERN) hat Heather Turner, J.D., ehemalige CEO von Carmot Therapeutics, in seinen Vorstand berufen. Turner bringt 25 Jahre Erfahrung in der Biotechnologie mit, zuletzt als sie die Übernahme von Carmot für 3,1 Milliarden Dollar durch Roche leitete. Sie ersetzt Ann E. Taylor, M.D., die nach drei Jahren im Dienst zurücktritt. Turners Fachkenntnisse erstrecken sich über die Bereiche Fettleibigkeit und Onkologie, mit früheren Führungsrollen bei Lyell Immunopharma, Sangamo Therapeutics und anderen biotechnologischen Unternehmen. Die Ernennung soll die strategische Entwicklung von Terns im Bereich der kleinmolekularen Produktkandidaten für schwere Krankheiten stärken.
- Appointment of experienced executive with successful track record (led $3.1B Carmot-Roche deal)
- Addition of strategic expertise in key therapeutic areas (obesity and oncology)
- Strengthened board expertise in drug development and commercialization
- Loss of three-year board member Dr. Ann Taylor's experience and continuity
Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company’s Board of Directors, effective immediately. In conjunction with Ms. Turner’s appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service.
“It is my pleasure to welcome Heather to the Terns Board, and I am confident she will be a valued thought partner. Heather brings relevant sector expertise in obesity and oncology and a deep understanding of the development of therapeutic products from research and development through to commercialization. We look forward to her insights and contribution to the strategic decisions that will strengthen and drive Terns’ further growth,” said Amy Burroughs, chief executive officer of Terns. “We thank Ann for her many contributions to Terns over the last three years as we have progressed innovative programs from research to the clinic.”
“I am delighted to be joining the Terns’ team as we advance a robust clinical development pipeline with the potential to transform patient care across serious metabolic diseases and oncology,” stated Ms. Turner. “I am excited to work with Terns’ talented leadership and Board to advance their novel, small molecule product candidates through clinical development to bring differentiated, new medicines to the patients who need them.”
Ms. Turner is a seasoned biotechnology executive with 25 years of experience across a range of therapeutic areas and stages of company development. Most recently, she served as Chief Executive Officer of Carmot Therapeutics, where she led the execution of a dual track IPO/strategic transaction process, which ultimately resulted in the acquisition of Carmot by Roche for
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about the Company within the meaning of the federal securities laws, including those related to expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company’s small-molecule product candidates; the potential for the mechanisms of action of the Company’s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company’s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company’s clinical trials; the Company’s clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company’s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company’s plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the potential commercialization of the Company’s product candidates; the Company’s plans and expectations around the addition of key personnel; and the Company’s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
Who is the new board member appointed to Terns Pharmaceuticals (TERN)?
What is Heather Turner's most significant recent achievement before joining TERN?
Which board member is leaving Terns Pharmaceuticals (TERN)?
What are Heather Turner's key areas of expertise relevant to TERN?
